Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib with Oral Topotecan in Metastatic Soft Tissue and Bone Sarcomas
NCT02357810Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Mar 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib and topotecan in soft tissue sarcoma (STS) and osteosarcoma (OS), sponsored by Northwestern University. Primary endpoint: Progression Free Rate at 12 Weeks. Started Mar 2015; status: completed.
02
Drugs
pazopanibtopotecan
03
Conditions
soft tissue sarcoma (STS)osteosarcoma (OS)
Beyond the preview
Go deeper on NCT02357810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02357810.